IN THE NEWS TODAY

“Genvio pharma limited announces the launch of IRETAVIR 0.5 and IRETAVIR 1 tablet are the trade name of Entecavir 0.5 mg and 1 mg respectively.”

Genvio Pharma Limited is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Our major therapeutic areas of focus are Oncology, ARV, Hormone and CNS.

“Bangladesh International Cancer Congress 2018”

This year “Bangladesh International Cancer Congress” was held on October 26-27 and Genvio Pharma Limited proudly participated in this program for the second time. It is considered to be one of the most significant events in the field of oncology and many foreign delegates joined this program to share their valuable thoughts and ideas.
Genvio Pharma Limited was very fortunate to demonstrate its stroke through stall activities with other pharmaceutical companies.

We are deeply saddened by the news of Tanvir Ahmed Shah (Sunny)’s sudden death. He was a loving son of Mr. Mohammad Shajahan, Chairman, Genvio Pharma Limited. Mr Tanvir Ahmed Shah was also one of shareholder of Genvio Pharma Limited.

On behalf of all Directors & Employees of Genvio Pharma Limited, we express our heartfelt respect to the departed soul and fervent prayer for the demised family. May Allah give his entire family the strength and the courage to bear this irreparable loss.

May his SOUL REST IN PEACE.

HR, Genvio Pharma Limited

Namaje Janaja of TANVIR AHMED SHAH SUNNY (30), youngest son of Mohammed Shajahan, Chairnam of Genvio,, who breathed his last on 15 October in Toronto, Canada; by a heart attack, will be held on Tuesday 23 October at 10am at Gulshan Society Masjid, Road 63 Gulshan 2.

He will be buried after the 2nd Janaja baad Zuhr at Baitujjalal Jame Masjid, Haji Jalal Ahmed Road in Lalpur, Fatullah, Narayanganj.

You are humbly requested to join the janajah and pray for the departed soul.

“Cancer Awareness Month Celebration”

Genvio Pharma Limited has proudly hosted a Cancer Screening & Awareness Program on 8th October 2018 at North South University. Experts from Anwar Khan Modern Medical College as well as Co- Founder and COO of Genvio Pharma Limited Mr. Ahmed Mustaq Zahangir shared their valuable thoughts with the audience regarding cancer and contemporary treatment pattern. The contribution of current pharma market in cancer treatment has been justified by the momentous speech of Mr. Zahangir during the awareness session.

Genvio Pharma Limited announced the launching of Sorafenib Tosylate INN 200 mg Tablet, introduced as the brand name “NOBOKIN”

Sorafenib is an anticancer medicine approved by US FDA for the treatment of,

1. Unresectable hepatocellular carcinoma (HCC).
2. Advanced renal cell carcinoma (RCC).

DOSAGE AND ADMINISTRATION
The recommended daily dose of NOBOKIN is 400 mg twice daily without food (at least 1 hour before or 2 hours after a meal). Treatment should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs.

Mechanism of Action
Sorafenib targets the adenosine triphosphate (ATP) binding site of multiple tyrosine kinase including vascular endothelial growth factor receptor (VEGFR) 1, 2 and 3, FMS-like tyrosine kinase 3 (FLT3), platelet derived growth factor receptor (PDGF), fibroblast growth factor receptor 1 (FGFR1), FMS-like tyrosine kinase 3 (Flt3), c-Kit protein (KIT) and RET receptor tyrosine kinase. These receptor tyrosine kinasea are important for tumor angiogenesis, proliferation and metastatic progression.

Please see the full prescribing information for details.
Link: NOBOKIN

IN THE GALLERY TODAY